Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200 Day Moving Average of $3.00

Predictive Oncology Inc. (NASDAQ:POAI) shares passed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $3.00 and traded as low as $1.35. Predictive Oncology shares last traded at $1.39, with a volume of 28,250 shares.

Predictive Oncology Trading Down 7.9 %

The business has a fifty day moving average of $2.69 and a 200-day moving average of $3.00. The firm has a market cap of $5.64 million, a PE ratio of -0.40 and a beta of 1.29.

Institutional Trading of Predictive Oncology

Institutional investors and hedge funds have recently modified their holdings of the business. Carnegie Mellon University purchased a new stake in shares of Predictive Oncology in the 4th quarter valued at about $34,000. Charles Schwab Investment Management Inc. purchased a new position in shares of Predictive Oncology during the 1st quarter valued at about $54,000. Virtu Financial LLC purchased a new position in shares of Predictive Oncology during the 1st quarter valued at about $66,000. Raymond James & Associates purchased a new position in shares of Predictive Oncology during the 3rd quarter valued at about $378,000. Finally, Citadel Advisors LLC purchased a new position in shares of Predictive Oncology during the 3rd quarter valued at about $65,000. Hedge funds and other institutional investors own 9.04% of the company’s stock.

Predictive Oncology Company Profile

Predictive Oncology Inc operates as a science-driven company on the oncology drug discovery. It provides various solutions for the oncology drug development. The company, through the integration of scientific rigor and machine learning, has developed the ability to advance molecules into medicine by introducing human diversity earlier into the discovery process with the pairing of artificial intelligence and the biobank of approximately 150K tumor samples.